Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
* The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications Allschwil, Switzerland - January 6, 2026 Idorsia Ltd (SIX: IDIA) announces the initiation of a Phase 2 proof-of-concept trial evaluating IDOR-1117-2520 for participants with moderate-to-severe psoriasis.
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
